Eaton Vance Management Atara Biotherapeutics, Inc. Transaction History

Eaton Vance Management

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 14, 2019	SELL	$28.4 - $41.74 $2.24 Million - $3.3 Million	-79,028 Closed	0 $0
Q4 2018 Feb 07, 2019	BUY	$30.9 - $42.97 $933,859 - $1.3 Million	30,222 Added 61.92%	79,028 $2.75 Million
Q2 2018 Aug 10, 2018	BUY	$35.15 - $51.45 $1.72 Million - $2.51 Million	48,806 New	48,806 $1.79 Million

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $616M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

Stay updated on Eaton Vance Management with notifications on news.